The formula was fine. The words were the risk.

A personal care brand assumed its regulatory exposure sat in the ingredient list. It sat in the marketing copy.

The situation

A brand preparing to launch a contoured bathing bar asked for a formulation review. The product included wintergreen oil, menthol, peppermint, eucalyptus, magnesium chloride and Epsom salt, and the brand was concerned those ingredients would push the product across the cosmetic-drug boundary.

The intended positioning leaned on recovery, muscle relief and physiotherapist endorsement.

What we found

Each ingredient of concern was present at a tenth of one percent. At those levels they are explicable as fragrance and sensory components, and the base composition supported classification as an ordinary toilet soap against the applicable national standard.

The risk was entirely on the pack. Classification is determined by the product as a whole, including intended use, label copy and advertising. Words like relief, soreness, stiffness, inflammation and injury recovery communicate a therapeutic intended use regardless of what the formula contains. A small-print disclaimer does not cure a therapeutic headline.

Classification follows the whole product, not the ingredient list.

What we did

We produced a claim-by-claim status matrix rather than a general warning. Each term was marked allowed, allowed with qualification, conditional or do not use, with the reasoning and a compliant alternative beside it. “Post-workout recovery” became “post-workout refresh.” Massage stayed, because it described the shape of the bar and the consumer’s own action rather than a service or a medicinal effect.

We also separated two things the brand had merged: the grade claim and the supplier specification. The percentage of soap noodle in a formula is not the same as the finished product’s total fatty matter, so we set a release condition that no grade or value be printed until finished-product testing confirmed it.

The outcome

The brand kept its formula, its format and its positioning, and launched with front-of-pack copy that carried the same consumer appeal without the drug-boundary exposure. Total engagement: one review cycle.

← The release result that belonged to a different product

A nine-fold result we advised the client not to claim →

Bring us the package before you commit the spend.

A single review cycle is usually enough to establish whether the data in hand describes the product you intend to sell.

All Case Studies